VOR
Vor Biopharma Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 2 to Apr 22 ▼ 11 days of insider sells: $49.4M by 1 insider, avg $16.46
- Jun 8 ▲ Vor Biopharma announced that China's NMPA conditionally approved tel…
- Jul 16 ▼ 1 insider sell $4.2K at $19.75
- Sep 29 ▲ Vor Bio announced positive post hoc Phase 3 data for telitacicept in…
- Sep 29 Contract: Telitacicept Demonstrates Deep and Durable Minimal Symptom…
- Oct 5 Activist stake: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule…
- Oct 21 William Blair initiates
- Oct 22 ▲ Vor Bio announced final two-year Phase 3 TELIGAN results for telitac…
- Oct 22 FDA: Telitacicept Demonstrates Durable Preservation of Kidney F…
- Oct 30 ▼ Earnings: VOR Q3 2026 Earnings: EPS $-1.45 (-74.1% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $49.4M.
- InstitutionsBULLISH
Q3 2026: 23 added (2 new), 4 trimmed or exited. Largest new: Federated Hermes, $14.5M.
- AnalystsBULLISH
12 of 14 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.933 → −$0.841 over 90 days. 2 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest +0.8% to 7.50M shares. 9.9 days to cover, ≈12.2% of shares.
- TrendRANGE
5% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $129.0M |
| FEDERATED HERMES, INC. | NEW | $14.5M |
| MARSHALL WACE, LLP | DOUBLED | $10.7M |
| AXIOM INVESTORS LLC /DE | ADD | $2.4M |
| MORGAN STANLEY | ADD | $1.9M |
| ALPS ADVISORS INC | ADD | $1.5M |
| JPMORGAN CHASE & CO | ADD | $630.5K |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $597.4K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
14 analystsPrice is below the lowest target. Median implies +111%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 21, 2026 | William Blair INITIATE | Outperform |
| Aug 12, 2026 | Wedbush MAINTAIN | Neutral |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Sokolove Jeremy Brett Chief Medical Officer Nov 2, 2026 | TAX W/H | $36.9K |
RA CAPITAL MANAGEMENT, L.P. 10%+ Owner Oct 2, 2026 | EXERCISE | $6.4K |
RA CAPITAL MANAGEMENT, L.P. 10%+ Owner Aug 24, 2026 | EXERCISE | $5.6K |
RA CAPITAL MANAGEMENT, L.P. 10%+ Owner Jul 16, 2026 | EXERCISE | $4.2K |
RA CAPITAL MANAGEMENT, L.P. 10%+ Owner Jul 16, 2026 | EXERCISE | $10.5M |
RA CAPITAL MANAGEMENT, L.P. 10%+ Owner Jul 16, 2026 | SELL | $4.2K |
ZACCARDELLI DAVID Director Jul 7, 2026 | AWARD | 42,658 sh |
Levin Andrew David Director Jun 11, 2026 | AWARD | 57,162 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.84 | -$0.95–-$0.64 | +11.7% | $0.00 |
| Next Q | -$0.99 | -$0.99–-$0.99 | No data | $0.00 |
| Current FY | -$6.67 | -$8.64–-$3.40 | -2.2% | $0.00 |
| Next FY | -$3.34 | -$3.90–-$2.53 | +12.3% | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
11 filings · 6 press releases · 0 bullish · 1 bearish · 10 neutral- NEUTRAL SC 13G/ANov 16, 2026
TCG Crossover GP II, LLC filed an amended Schedule 13G disclosing beneficial ownership of 2,836,539 shares of Vor Biopharma common stock as of September 30, 2026, representing 4.6% of shares outstanding. This is a decrease from the prior filing (2,836,539 shares vs. 2,836,539 shares at the prior…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 12, 2026
Vor Biopharma expanded its license agreement with RemeGen to include RC298, a next-generation dual…
Monitor IND filing for RC298 in H1 2027 and any progress in telitacicept Phase 3 trials. The $150M ATM facility and warrant dilution create overhang; watch for any ATM usage or warrant exercises.
- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing beneficial ownership of 6,318,525…
Fidelity's passive stake is unchanged at 10.7%. No signal of increased conviction or exit. Monitor next filing for any change in position or conversion to 13D.
- BEARISH 424B5Oct 30, 2026
Vor Biopharma filed a 424B5 prospectus supplement establishing a new at-the-market (ATM) equity…
Monitor periodic 10-Q filings for actual ATM sales volume and remaining capacity under the program. The company's heavy reliance on equity financing (13 offerings in 24 months) and large warrant…
All VOR filing & press-release reports (17)
- SC 13G/A reportNov 16, 2026
- 8-K reportNov 12, 2026
- SC 13G/A reportNov 5, 2026
- 424B5 reportOct 30, 2026
- PRESS-RELEASE reportOct 30, 2026
- PRESS-RELEASE reportOct 22, 2026
- PRESS-RELEASE reportOct 5, 2026
- PRESS-RELEASE reportSep 29, 2026
- PRESS-RELEASE reportAug 11, 2026
- 3 reportJul 9, 2026
- INST-CLUSTER reportJun 11, 2026
- PRESS-RELEASE reportJun 8, 2026
- EFFECT reportMay 7, 2026
- S-3 reportApr 27, 2026
- DEFA14A reportApr 27, 2026
- PRESS-RELEASE reportMar 27, 2026
- PRESS-RELEASE reportMar 23, 2026